Tell us what you think about Healio
Sign in for a personal experience.
Customized content served to meet your interests.
PARIS — Two studies presented here show that the CoreValve transcatheter aortic valve replacement system results in low mortality and stroke rates at 1 year and is cost effective in patients at high surgical risk.
Both studies featured data from the ADVANCE trial, which looked at “real-world” outcomes of the CoreValve TAVR system (Medtronic) in 1,015 patients from 44 centers in 12 countries in Western Europe, Asia and South America. The TAVR device was implanted in 996 patients with severe aortic stenosis who were deemed high risk for surgery.
Register for Healio to get content tailored to your specialty and areas of interest.
It’s FREE and only takes one minute.
View past polls »
©2013 All Rights Reserved.